New inhaled drug for lung scarring passes first safety tests in healthy volunteers
NCT ID NCT06746064
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This early-stage study tested the safety and how the body handles an experimental inhaled drug called CHF10073. It involved 155 healthy volunteers who received single or multiple doses. The goal was to check for side effects and measure drug levels, not to treat the disease. This information will help design future studies for people with pulmonary fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium NV Clinical Pharmacology Unit
Edegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.